Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Eric Lawitz, Manuel Romero-Gómez, Quentin M. Anstee, Stephen A. Harrison, Catherine Jia, Zobair M. Younossi, Chuhan Chung, Zachary Goodman, Robert P. Myers, Ryan S Huss, Michael Trauner, Vincent Wai-Sun Wong, Andrew J. Muir, Takeshi Okanoue, Jaime Bosch, D. Ding, Nezam H. Afdhal, Manal F. Abdelmalek, Ling Han, Arun J. Sanyal
Publikováno v:
Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M and Myers, Robert P (2022). Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. Hepatology, 75(5), pp. 1235-1246. Wiley 10.1002/hep.32204
[Background and Aims] Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver‐related complications
Autor:
Don C. Rockey, Andrew H. Beck, Murray B. Resnick, Nezam H. Afdhal, Michael Christopher Montalto, Oscar Carrasco-Zevallos, Catherine Jia, Zachary Goodman, Harsha Pokkalla, Mitchell L. Shiffman, Zahil Shanis, Ling Han, Jaime Bosch, Manal F. Abdelmalek, Arun J. Sanyal, Quang Huy Le, Chuhan Chung, Robert P. Myers, Ilan Wapinski, Stephen A. Harrison, Dinkar Juyal
Publikováno v:
Bosch, Jaime; Chung, Chuhan; Carrasco-Zevallos, Oscar M; Harrison, Stephen A; Abdelmalek, Manal F; Shiffman, Mitchell L; Rockey, Don C; Shanis, Zahil; Juyal, Dinkar; Pokkalla, Harsha; Le, Quang Huy; Resnick, Murray; Montalto, Michael; Beck, Andrew H; Wapinski, Ilan; Han, Ling; Jia, Catherine; Goodman, Zachary; Afdhal, Nezam; Myers, Robert P; ... (2021). A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 74(6), pp. 3146-3160. Wiley 10.1002/hep.32087
BACKGROUND AND AIMS The hepatic venous pressure gradient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretation. We hypothesized that HVPG could be extrapolated from liver histology using a machine learning (M
Autor:
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad H. Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M. Robinson, David T. Hagerty, Jean L. Chan, Arun J. Sanyal, M. Abdelmalek, K. Bhamidimarri, B. Borg, S. Caldwell, J. Fenkel, B. Freilich, M. Fuchs, M. Ghabril, R. Ghalib, S. Gonzalez, S. Gordon, B. Hameed, S. Harrison, Z. Kayali, N. Kemmer, K. Korenblat, M. Lai, C. Landis, E. Lawitz, W. Lee, S. Lidofsky, E. Mena, M. Noureddin, A. Paredes, N. Pyrsopoulos, R. Reddy, M. Rinella, D. Rockey, M. Rodriguez, M. Ryan, S. Sarkar, S. Satapathy, A. Scanga, M. Shiffman, M. Siddiqui, D. Simonetto, W. Syn, P. Thuluvath, R. Vemulapalli, J. Vierling, Z. Younes, A. Albillos, J. Arenas Ruiz-Tapiador, S. Augustin, J. Calleja, J. Crespo Garcia, L. Garcia Buey, J.C. Garcia-Pagan, C. Villanueva, C. Bureau, N. Carbonell, V. Leroy, P.-E. Rautou, H. Heinzow, I. Schiefke, A. Zipprich, A. Berzigotti, B. Muellhaupt
Publikováno v:
Garcia-Tsao, Guadalupe; Bosch, Jaime; Kayali, Zeid; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric; Satapathy, Sanjaya K; Ghabril, Marwan; Shiffman, Mitchell L; Younes, Ziad H; Thuluvath, Paul J; Berzigotti, Annalisa; Albillos, Agustin; Robinson, James M; Hagerty, David T; Chan, Jean L; Sanyal, Arun J (2020). Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. Journal of hepatology, 72(5), pp. 885-895. Elsevier 10.1016/j.jhep.2019.12.010
Background & Aims Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG)
Autor:
Danielle, Brandman, Marie, Boyle, Stuart, McPherson, Mark L, Van Natta, Arun J, Sanyal, Kris, Kowdley, Brent, Neuschwander-Tetri, Naga, Chalasani, Manal F, Abdelmalek, Norah A, Terrault, Art, McCullough, Ricki, Bettencourt, Cyrielle, Caussy, David E, Kleiner, Cynthia, Behling, James, Tonascia, Quentin M, Anstee, Rohit, Loomba
Publikováno v:
Aliment Pharmacol Ther
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2022, 55 (11), pp.1441-1451. ⟨10.1111/apt.16874⟩
Alimentary Pharmacology and Therapeuthics
Alimentary Pharmacology and Therapeuthics, 2022, 55 (11), pp.1441-1451. ⟨10.1111/apt.16874⟩
International audience; BACKGROUND AND AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis benefit from referral to subspecialty care. While several clinical prediction rules exist to identify advanced fibrosis, the cutoff for excl
Autor:
Manal F. Abdelmalek, Keri A. Seymour
Publikováno v:
Current opinion in gastroenterology. 37(3)
Purpose of review Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States and increasing globally. The progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), can lead to cirrhosis and compl
Autor:
C. Stephen Djedjos, Raul Aguilar Schall, Zachary Goodman, B. Mccolgan, G. Mani Subramanian, Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, Vlad Ratziu, Zobair M. Younossi, Manal F. Abdelmalek, Arun J. Sanyal, Stephen H. Caldwell, Mitchell L. Shiffman, Catherine Jia, John G. McHutchison, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Hepatology
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridg
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
B. Mccolgan, Eric Lawitz, Anna Mae Diehl, Catherine Jia, Manal F. Abdelmalek, Jaime Bosch, Zobair M. Younossi, G. Mani Subramanian, Mitchell L. Shiffman, John G. McHutchison, Reem Ghalib, Nezam H. Afdhal, Don C. Rockey, Andrew J. Muir, Raul Aguilar Schall, Vlad Ratziu, Zachary Goodman, Stephen H. Caldwell, Arun J. Sanyal, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Gastroenterology. 155:1140-1153
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients wit
Autor:
Sarah E. Kleinstein, David Goldstein, Cynthia A. Moylan, Cynthia D. Guy, Anna Mae Diehl, Manal F. Abdelmalek, Matthew Rein
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH)
Autor:
Sven Francque, Frank M. Sacks, Michael Roden, Jean-François Dufour, Frank Tacke, Christopher D. Byrne, Gyongyi Szabo, Kenneth Cusi, Manal F. Abdelmalek
Publikováno v:
Nature Reviews Gastroenterology and Hepatology
The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the